


Searching News Database: Satiety
HSMN NewsFeed - 19 Jan 2022
Titan SGS(R) from Standard Bariatrics, Inc. Passes 1,000 Clinical Case Uses
Titan SGS(R) from Standard Bariatrics, Inc. Passes 1,000 Clinical Case Uses
HSMN NewsFeed - 4 May 2021
Standard Bariatrics(R) Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance
Standard Bariatrics(R) Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance
HSMN NewsFeed - 14 Feb 2013
Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
HSMN NewsFeed - 23 Dec 2011
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
HSMN NewsFeed - 5 Aug 2011
Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
HSMN NewsFeed - 20 Dec 2010
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
HSMN NewsFeed - 10 Nov 2010
Satiety’s TOGA(R) System Named a Top Medical Innovation by Cleveland Clinic Experts
Satiety’s TOGA(R) System Named a Top Medical Innovation by Cleveland Clinic Experts
HSMN NewsFeed - 29 Dec 2009
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
HSMN NewsFeed - 7 May 2009
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
HSMN NewsFeed - 12 Sep 2006
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
Additional items found! 8
Members Archive contains
8 additional stories matching:
Satiety
(Password required)
Satiety
(Password required)
